Francesca D'Addio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2559793/publications.pdf

Version: 2024-02-01

63 papers 2,838 citations

29 h-index

172386

51 g-index

64 all docs

64
docs citations

times ranked

64

4400 citing authors

#	Article	IF	CITATIONS
1	The IGFBP3/TMEM219 pathway regulates beta cell homeostasis. Nature Communications, 2022, 13, 684.	5.8	16
2	Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccines in a Cohort of Patients With Type 1 Diabetes. Diabetes, 2022, 71 , $1800-1806$.	0.3	20
3	Abnormalities of the oculomotor function in type 1 diabetes and diabetic neuropathy. Acta Diabetologica, 2022, 59, 1157-1167.	1.2	1
4	Inflammation and vascular dysfunction: The negative synergistic combination of diabetes and COVIDâ€19. Diabetes/Metabolism Research and Reviews, 2022, 38, .	1.7	7
5	Reply to letter to the editor regarding "Use of DPP-4 inhibitors in patients with COVID-19― Acta Diabetologica, 2021, 58, 247-248.	1.2	1
6	Continuous glucose monitoring in patients with type 2 diabetes on hemodialysis. Acta Diabetologica, 2021, 58, 975-981.	1.2	9
7	Regulatory B Cells in Autoimmune Diabetes. Journal of Immunology, 2021, 206, 1117-1125.	0.4	6
8	Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nature Metabolism, 2021, 3, 774-785.	5.1	259
9	miR-21 antagonism reprograms macrophage metabolism and abrogates chronic allograft vasculopathy. American Journal of Transplantation, 2021, 21, 3280-3295.	2.6	14
10	Hematopoietic Stem Cells in Type 1 Diabetes. Frontiers in Immunology, 2021, 12, 694118.	2.2	7
11	The IL-8-CXCR1/2 axis contributes to diabetic kidney disease. Metabolism: Clinical and Experimental, 2021, 121, 154804.	1.5	22
12	Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacological Research, 2021, 171, 105782.	3.1	72
13	Strictureplasties performed by laparoscopic approach for complicated Crohn's disease. A prospective, observational, cohort study. Digestive and Liver Disease, 2021, 53, 1286-1293.	0.4	7
14	Next-gen therapeutics to spare and expand beta-cell mass. Current Opinion in Pharmacology, 2021, 61, 77-82.	1.7	3
15	PD-1 blockade counteracts post–COVID-19 immune abnormalities and stimulates the anti–SARS-CoV-2 immune response. JCI Insight, 2021, 6, .	2.3	51
16	The \hat{I}^2 -cell effect of verapamil-based treatment in patients with type 2 diabetes: a systematic review. Acta Diabetologica, 2020, 57, 117-131.	1,2	8
17	Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. Diabetes Care, 2020, 43, 2999-3006.	4.3	201
18	Embryonic stem cell extracts improve wound healing in diabetic mice. Acta Diabetologica, 2020, 57, 883-890.	1.2	26

#	Article	IF	CITATIONS
19	Placental proteome abnormalities in women with gestational diabetes and large-for-gestational-age newborns. BMJ Open Diabetes Research and Care, 2020, 8, e001586.	1.2	13
20	The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis. Acta Diabetologica, 2019, 56, 341-354.	1.2	29
21	Sodium glucose cotransporters inhibitors in type 1 diabetes. Pharmacological Research, 2018, 133, 1-8.	3.1	20
22	Islet-Derived eATP Fuels Autoreactive CD8+ T Cells and Facilitates the Onset of Type 1 Diabetes. Diabetes, 2018, 67, 2038-2053.	0.3	17
23	Prostaglandin E2 Stimulates the Expansion of Regulatory Hematopoietic Stem and Progenitor Cells in Type 1 Diabetes. Frontiers in Immunology, 2018, 9, 1387.	2.2	15
24	P2X7R mutation disrupts the NLRP3-mediated Th program and predicts poor cardiac allograft outcomes. Journal of Clinical Investigation, 2018, 128, 3490-3503.	3.9	31
25	Immunotherapy for type 1 diabetes. Journal of Endocrinological Investigation, 2017, 40, 803-814.	1.8	30
26	Immunoevasion rather than intrinsic oncogenicity may confer MSCs from non-obese diabetic mice the ability to generate neural tumors. Acta Diabetologica, 2017, 54, 707-712.	1.2	0
27	PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes. Science Translational Medicine, 2017, 9, .	5.8	99
28	Metabolomic Profiling in Individuals with a Failing Kidney Allograft. PLoS ONE, 2017, 12, e0169077.	1.1	39
29	Type 1 Diabetes and Dysfunctional Intestinal Homeostasis. Trends in Endocrinology and Metabolism, 2016, 27, 493-503.	3.1	32
30	The use of hematopoietic stem cells in autoimmune diseases. Regenerative Medicine, 2016, 11, 395-405.	0.8	12
31	TIM4 Regulates the Anti-Islet Th2 Alloimmune Response. Cell Transplantation, 2015, 24, 1599-1614.	1.2	9
32	Co-transplantation of autologous MSCs delays islet allograft rejection and generates a local immunoprivileged site. Acta Diabetologica, 2015, 52, 917-927.	1.2	87
33	Circulating IGF-I and IGFBP3 Levels Control Human Colonic Stem Cell Function and Are Disrupted in Diabetic Enteropathy. Cell Stem Cell, 2015, 17, 486-498.	5.2	60
34	The rise, fall, and resurgence of immunotherapy in type 1 diabetes. Pharmacological Research, 2015, 98, 31-38.	3.1	49
35	Interleukin-10+ Regulatory B Cells Arise Within Antigen-Experienced CD40+ B Cells to Maintain Tolerance to Islet Autoantigens. Diabetes, 2015, 64, 158-171.	0.3	80
36	Novel therapeutic and diagnostic management of heart transplant patients. Heart, Lung and Vessels, 2015, 7, 198-207.	0.4	1

#	Article	IF	CITATIONS
37	Role of Podocyte B7-1 in Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2014, 25, 1415-1429.	3.0	114
38	Islet Transplantation Stabilizes Hemostatic Abnormalities and Cerebral Metabolism in Individuals With Type 1 Diabetes. Diabetes Care, 2014, 37, 267-276.	4.3	39
39	Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in New-Onset Type 1 Diabetes: A Multicenter Analysis. Diabetes, 2014, 63, 3041-3046.	0.3	122
40	Harnessing the immunological properties of stem cells as a therapeutic option for diabetic nephropathy. Acta Diabetologica, 2014, 51, 897-904.	1.2	32
41	Positive effects of a novel non-peptidyl low molecular weight radical scavenger in renal ischemia/reperfusion: a preliminary report. SpringerPlus, 2014, 3, 158.	1.2	6
42	B7h (ICOS-L) Maintains Tolerance at the Fetomaternal Interface. American Journal of Pathology, 2013, 182, 2204-2213.	1.9	30
43	Long-Term Heart Transplant Survival by Targeting the Ionotropic Purinergic Receptor P2X7. Circulation, 2013, 127, 463-475.	1.6	91
44	Effect of the Purinergic Inhibitor Oxidized ATP in a Model of Islet Allograft Rejection. Diabetes, 2013, 62, 1665-1675.	0.3	73
45	Prolonged, Low-Dose Anti-Thymocyte Globulin, Combined with CTLA4-lg, Promotes Engraftment in a Stringent Transplant Model. PLoS ONE, 2013, 8, e53797.	1.1	12
46	CD160lg Fusion Protein Targets a Novel Costimulatory Pathway and Prolongs Allograft Survival. PLoS ONE, 2013, 8, e60391.	1.1	25
47	Near Normalization of Metabolic and Functional Features of the Central Nervous System in Type 1 Diabetic Patients With End-Stage Renal Disease After Kidney-Pancreas Transplantation. Diabetes Care, 2012, 35, 367-374.	4.3	36
48	The Link between the PDL1 Costimulatory Pathway and Th17 in Fetomaternal Tolerance. Journal of Immunology, 2011, 187, 4530-4541.	0.4	145
49	Kidney-Pancreas Transplantation Is Associated With Near-Normal Sexual Function in Uremic Type 1 Diabetic Patients. Transplantation, 2011, 92, 802-808.	0.5	21
50	Targeting the CXCR4–CXCL12 Axis Mobilizes Autologous Hematopoietic Stem Cells and Prolongs Islet Allograft Survival via Programmed Death Ligand 1. Journal of Immunology, 2011, 186, 121-131.	0.4	71
51	A Novel Clinically Relevant Approach to Tip the Balance Toward Regulation in Stringent Transplant Model. Transplantation, 2010, 90, 260-269.	0.5	40
52	A Novel Clinically Relevant Strategy to Abrogate Autoimmunity and Regulate Alloimmunity in NOD Mice. Diabetes, 2010, 59, 2253-2264.	0.3	62
53	TIM-3: A Novel Regulatory Molecule of Alloimmune Activation. Journal of Immunology, 2010, 185, 5806-5819.	0.4	69
54	Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 10734-10739.	3.3	64

#	Article	IF	Citations
55	An In Vivo Autotransplant Model of Renal Preservation: Cold Storage Versus Machine Perfusion in the Prevention of Ischemia/Reperfusion Injury. Artificial Organs, 2009, 33, 565-570.	1.0	29
56	5-Methyltetrahydrofolate Administration Is Associated with Prolonged Survival and Reduced Inflammation in ESRD Patients. American Journal of Nephrology, 2008, 28, 941-948.	1.4	35
57	A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. Journal of Experimental Medicine, 2008, 205, 3133-3144.	4.2	277
58	Metabolic and Immunological Features of the Failing Islet-Transplanted Patient. Diabetes Care, 2008, 31, 436-438.	4.3	23
59	Nephrological Indications in Combined Liver-Kidney Transplantation. Transplantation Proceedings, 2006, 38, 1086-1088.	0.3	8
60	Combined Liver-Kidney Transplantationâ€"S. Orsola Experience: Nephrological Aspects. Transplantation Proceedings, 2006, 38, 1122-1124.	0.3	10
61	Standard Heparin versus Low-Molecular-Weight Heparin. Nephron, 2002, 92, 589-600.	0.9	42
62	In vivo Evaluation of Cellular and Inflammatory Response to a New Polyethersulfone Membrane., 2002, 138, 68-79.		4
63	Platelet Activation and PDGF-AB Release during Dialysis. International Journal of Artificial Organs, 2002, 25, 1128-1136.	0.7	5